A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects (BT-HC034S-101)
A Phase I, Randomized, Double-Blind, Positive-Controlled, Parallel-Group Pharmacokinetic Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Xiaoai He
- 전화번호: +86-1500-897-1099
- 이메일: 15008971099@126.com
연구 장소
-
-
Hainan
-
Haikou, Hainan, 중국, 570208
- 모병
- Haikou People's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
- Be able to complete the study as required by the study protocol;
- Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
- Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).
Exclusion Criteria:
- Subjects with allergic diathesis, or history of food/drug allergy within recent 4 weeks, especially hypersensitivity to any component of investigational product or excipients;
- Blood donation or substantial blood loss (>200 mL) within 3 months, or platelet donation within 2 weeks prior to investigational product administration;
- Major surgery within 6 months prior to first dosing, or planned surgery during study;
- Hereditary bleeding tendency, coagulation disorders, or history of thrombosis / hemorrhagic diseases;
- Prior treatment with EGFR-targeted agents;
- Use of prescription / over-the-counter drugs or nutritional supplements within 5 half-lives of the product OR within 2 weeks before study drug administration (whichever is longer). Discontinue traditional Chinese medicinal supplements 28 days prior to study drug administration, except for topical products with no systemic absorption.
- Clinically significant abnormalities as assessed by investigator in vital signs (SBP <90 mmHg or >140 mmHg; DBP >90 mmHg), physical examination, ECG (resting heart rate <50 or >100 beats/min), laboratory tests (blood biochemistry, CBC, urinalysis, coagulation);
- Presence of any investigator-identified clinically significant disease, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, cardiovascular and cerebrovascular disorders;
- History of hepatitis B, hepatitis C, AIDS, syphilis, or clinically significant abnormality in ≥1 item of infectious disease four-panel screening;
- Alcohol intake ≥14 units/week within 3 months pre-screening (1 unit = 285 mL beer, 25 mL 40%-ABV spirits, 150 mL 12%-ABV wine); alcohol-containing products consumed within 24 h prior to study drug dosing; positive alcohol breath test at screening;
- Cigarette smoking ≥5 cigarettes/day within 3 months pre-screening;
- Drug abuse history within 5 years, illicit drug use within 3 months before screening, habitual use of any medicines (including herbal medicines), or positive urine drug screen.
- Participation in any drug clinical trial with investigational product administration, or medical device trial receiving device treatment, or use of drugs of the same class within 3 months prior to screening;
- Receipt of live-attenuated vaccines within 14 days prior to first dosing, or planned live-attenuated vaccination during study;
- Intolerance to venipuncture blood collection, or history of needle-phobia or hematophobia;
- Any subject who, in investigator's judgment, may be unable to provide informed consent or follow the protocol; whose participation may bias study results or endanger subject safety; or otherwise considered unsuitable for study enrollment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: HC034S
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first HC034S injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
|
활성 비교기: China-sourced Erbitux®
|
Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first cetuximab injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Area under the serum concentration-time curve from time 0 to infinity (AUC0-∞)
기간: Up to Day 29
|
Up to Day 29
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
quantifiable concentration (AUC₀-t)
기간: Up to Day 29
|
Up to Day 29
|
|
Maximum serum concentration (Cmax)
기간: Up to Day 29
|
Up to Day 29
|
|
Time to reach maximum serum concentration (Tmax)
기간: Up to Day 29
|
Up to Day 29
|
|
Total clearance (CL)
기간: Up to Day 29
|
Up to Day 29
|
|
Terminal elimination half-life (t1/2)
기간: Up to Day 29
|
Up to Day 29
|
|
Apparent volume of distribution (Vd)
기간: Up to Day 29
|
Up to Day 29
|
|
Apparent terminal elimination rate constant (λz)
기간: Up to Day 29
|
Up to Day 29
|
|
Percentage of the area-under-the-curve extrapolated to infinity (AUC_%Extrap)
기간: Up to Day 29
|
Up to Day 29
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) following study drug administration, including electrocardiograms (ECG), laboratory test parameters, physical examinations, and vital signs.
기간: Up to Day 29
|
Up to Day 29
|
|
Positive incidence, titer and duration of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)
기간: Up to Day 29
|
Up to Day 29
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- HC034S-101
- BT-HC034S-101 (기타 식별자: Shanghai Hongcheng Pharmaceutical Co., Ltd.)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .